Fagron N.V.

Regulatory Filings • Oct 27, 2025

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 24 October 2025 – 6PM CET

Fagron's share buy-back program: Weekly update

In the period from 20 October 2025 through 24 October 2025, Fagron purchased 45,000 of its owns shares at an average price of €21.0115 per share corresponding to a total amount of €945,517.50.

These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron's obligations under its long-term incentive scheme, which was announced on 9 October 2025.

The total number of own shares purchased to date is 65,000.

More information, including a detailed overview of the purchase transactions under this program, is available on our share buy-back webpage.

Financial calendar

12 February 2026 Full year results 2025 9 April 2026 Trading update first quarter 2026 30 July 2026 Half year results 2026

Further information

Ignacio Artola Global Investor Relations Leader Ignacio.artola@fagron.com

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR'. Fagron's operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

Important information regarding forward-looking statements

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.